These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 9792976)
1. Efficacy of skeletal alkaline phosphatase and prostate-specific antigen in the diagnosis of bone metastasis in cancer of the prostate. Wolff JM; Ittel T; Borchers H; Brauers A; Jakse G Urol Int; 1998 Oct; 61(1):12-6. PubMed ID: 9792976 [TBL] [Abstract][Full Text] [Related]
2. Skeletal alkaline phosphatase in the metastatic workup of patients with prostate cancer. Wolff JM; Ittel T; Boeckmann W; Reinike T; Habib FK; Jakse G Eur Urol; 1996; 30(3):302-6. PubMed ID: 8931961 [TBL] [Abstract][Full Text] [Related]
3. [Is skeletal alkaline phosphatase a valid staging marker in detection of osteoblastic skeletal metastases of prostate carcinoma?]. Wirtz DC; Wolff JM; Ittel TH; Jakse G; Niethard FU Z Orthop Ihre Grenzgeb; 1998; 136(3):255-9. PubMed ID: 9736988 [TBL] [Abstract][Full Text] [Related]
4. Metastatic workup of patients with prostate cancer employing alkaline phosphatase and skeletal alkaline phosphatase. Wolff JM; Ittel TH; Borchers H; Boekels O; Jakse G Anticancer Res; 1999; 19(4A):2653-5. PubMed ID: 10470213 [TBL] [Abstract][Full Text] [Related]
5. Metastatic workup of patients with prostate cancer employing skeletal alkaline phosphatase. Wolff JM; Ittel TH; Boeckmann W; Habib FK; Jakse G Anticancer Res; 1997; 17(4B):2995-7. PubMed ID: 9329584 [TBL] [Abstract][Full Text] [Related]
6. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen. Morote J; Lorente JA; Encabo G Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009 [TBL] [Abstract][Full Text] [Related]
7. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Lorente JA; Valenzuela H; Morote J; Gelabert A Eur J Nucl Med; 1999 Jun; 26(6):625-32. PubMed ID: 10369948 [TBL] [Abstract][Full Text] [Related]
8. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases. Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113 [TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. Lorente JA; Morote J; Raventos C; Encabo G; Valenzuela H J Urol; 1996 Apr; 155(4):1348-51. PubMed ID: 8632571 [TBL] [Abstract][Full Text] [Related]
10. Skeletal alkaline phosphatase: a marker for individual follow-up in patients with advanced prostatic cancer. Wechsel HW; Petri E; Bichler KH Urol Int; 1997; 58(2):80-3. PubMed ID: 9096267 [TBL] [Abstract][Full Text] [Related]
11. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. Wymenga LF; Boomsma JH; Groenier K; Piers DA; Mensink HJ BJU Int; 2001 Aug; 88(3):226-30. PubMed ID: 11488734 [TBL] [Abstract][Full Text] [Related]
12. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459 [TBL] [Abstract][Full Text] [Related]
13. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer. Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119 [TBL] [Abstract][Full Text] [Related]
14. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Wolff JM; Zimny M; Borchers H; Wildberger J; Buell U; Jakse G Eur Urol; 1998; 33(4):376-81. PubMed ID: 9612680 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer. Murphy GP; Troychak MJ; Cobb OE; Bowes VA; Kenny RJ; Barren RJ; Kenny GM; Ragde H; Holmes EH; Wolfert RL Prostate; 1997 Oct; 33(2):141-6. PubMed ID: 9316655 [TBL] [Abstract][Full Text] [Related]
16. [Relationship of serum prostate-specific antigen and alkaline phosphatase levels with bone metastases in patients with prostate cancer]. Wang ZL; Wang XF Zhonghua Nan Ke Xue; 2005 Nov; 11(11):825-7. PubMed ID: 16333960 [TBL] [Abstract][Full Text] [Related]
17. Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer. Cooper EH; Whelan P; Purves D Prostate; 1994 Nov; 25(5):236-42. PubMed ID: 7526352 [TBL] [Abstract][Full Text] [Related]
18. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis. Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975 [TBL] [Abstract][Full Text] [Related]
19. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer. Salminen E; Ala-Houhala M; Korpela J; Varpula M; Tiitinen SL; Halleen JM; Väänänen HK Acta Oncol; 2005; 44(7):742-7. PubMed ID: 16227166 [TBL] [Abstract][Full Text] [Related]
20. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase. Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H Int J Urol; 1997 Nov; 4(6):572-5. PubMed ID: 9477186 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]